Statute Details
- Title: Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations
- Act Code: MA1975-RG1
- Type: Subsidiary Legislation (sl)
- Authorising Act: Medicines Act (Chapter 176, Section 74)
- Citation / Regulation Number: Rg 1
- Gazette / Instrument: G.N. No. S 145/1977
- Revised Edition: 2000 RevEd (31 January 2000)
- Status: Current version as at 27 March 2026
- Commencement Date: Not stated in the provided extract
- Key Provisions (from extract): Regulations 3–14 (including licence validity, applications, ongoing duties, records, substandard products, fees, and penalties)
What Is This Legislation About?
The Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations (“the Regulations”) form part of Singapore’s regulatory framework for veterinary medicines. In practical terms, they control two critical points in the lifecycle of veterinary medicinal products: (1) whether a product may be placed on the market (through a product licence), and (2) whether a specific shipment may be brought into Singapore (through an import licence).
The Regulations are designed to ensure that veterinary medicinal products used for animals in Singapore meet baseline requirements for safety, quality, and efficacy, and that the licensing authority can monitor products after approval. They do this by requiring applicants to submit detailed scientific and testing information, imposing ongoing reporting obligations on licence holders, and requiring importers to keep records that enable inspection and traceability.
Although the Regulations are relatively short, they impose a structured compliance regime. They distinguish between a full product licence and a provisional product licence, set time limits for each, require separate applications per product (with limited bundling where strengths/proportions are the same), and create enforcement mechanisms including directions to withhold suspected substandard products and criminal penalties for non-compliance.
What Are the Key Provisions?
1. Licence validity periods (Regulations 3 and 4)
Regulation 3 governs the duration of product licences. A product licence (other than a provisional product licence) is granted for 5 years, or any shorter period the licensing authority may determine. A provisional product licence is granted for 2 years, or any shorter period. This creates a staged approval pathway: provisional licences may be used where the authority is not yet satisfied to grant full approval for the longer term, or where additional information is expected.
Regulation 4 governs import licences. Each import licence is valid only for one consignment of veterinary medicinal products for which the application was made. It is also time-limited: it is in force for one month from the date of issue. For importers, this means operational planning is essential—shipments must align with the licence window, and “blanket” import permissions are not permitted under these Regulations.
2. Application requirements and submission of particulars (Regulations 5 and 6)
Regulation 5 sets the procedural foundation. Applications for a product licence or provisional product licence must be made to the licensing authority in the required form and manner, accompanied by the information, documents, samples, and other material the authority may require. Critically, Regulation 5(2) requires a separate application for each veterinary medicinal product. This is a compliance trap for applicants who attempt to treat different products as one application.
However, Regulation 5(3) allows a limited consolidation: a single application may cover 2 or more veterinary medicinal products if they have the same pharmaceutical form and consist of either (a) a single active constituent in different strengths, or (b) a mixture of two or more active constituents of different strengths but in the same proportion. For practitioners, this provision is important when advising on product families (e.g., dose-ranging variants) and structuring submissions to avoid unnecessary duplication while staying within the statutory boundaries.
Regulation 6 is the substantive content requirement. Applicants must submit particulars the licensing authority may require, including: (a) chemical, pharmaceutical, experimental, and biological studies; (b) animal tests and studies; (c) possible hazards to man, livestock, and wildlife; and (d) precautions or contra-indications. In effect, the Regulations codify a safety-and-efficacy evidence package and require hazard analysis and risk mitigation information. This is particularly relevant for counsel advising on regulatory strategy, because the scope of required data is broad and explicitly includes both animal testing and human/animal/wildlife hazard considerations.
3. Ongoing duties: changes, new information, adverse effects, and withdrawal (Regulations 7–10)
Once a licence is granted, the Regulations impose continuous regulatory communication duties. Regulation 7 requires the holder to forthwith inform the licensing authority of any material change made or proposed in the particulars contained in the application. The Regulation specifies the types of changes that matter: changes in product specification; changes in constituent specifications; changes in composition; and changes in methods and procedures used to ensure compliance with product specifications. “Material change” is not defined in the extract, but the enumerated categories indicate that changes affecting identity, composition, manufacturing controls, or compliance procedures are likely to be treated as material.
Regulation 8 requires the holder to inform the authority forthwith of any information received that casts doubt on the continued validity of data submitted for assessing safety, quality, or efficacy. This is a forward-looking obligation: even if the product has not yet caused harm, new evidence that undermines the original assessment must be reported.
Regulation 9 creates a pharmacovigilance-like duty. The holder must inform the licensing authority of reports of adverse effects on human beings or animals (or both) associated with the use of the veterinary medicinal product or its constituents. The licensing authority may also require the holder to furnish copies of such reports. This provision is important for practitioners because it links licence compliance to post-market safety monitoring and reporting.
Regulation 10 requires notification of withdrawal from sale, supply, or exportation. If the holder decides to withdraw any veterinary medicinal product, it must notify the licensing authority forthwith and state the reason. This ensures the authority can manage regulatory and public health implications, including potential gaps in supply or the need for risk communications.
4. Records, substandard products, fees, and penalties (Regulations 11–14)
Regulation 11 imposes recordkeeping obligations on importers (not necessarily on all licence holders, depending on role). Importers must keep records of imports and distribution of veterinary medicinal products readily available for inspection. When directed, they must submit the records. Records must not be destroyed for 5 years from the date of importation, and must facilitate withholding from sale, supply, or exportation of any veterinary medicinal products. This is a traceability requirement: it supports rapid regulatory action if a product is later found to be non-compliant.
Regulation 12 addresses quality failures. Where a veterinary medicinal product is suspected or found not to conform as regards strength, quality, or purity with the product specification or with the Medicines Act or regulations, the licensing authority may direct the importer or any person in possession to withhold the product from sale, supply, or exportation for a specified period. This is a powerful interim control measure and should be treated as a potential operational and legal risk: counsel should advise clients on response protocols, segregation of stock, and documentation to demonstrate compliance with directions.
Regulation 13 sets fees: $3 per consignment for an import licence; $50 per product for a product licence; and $25 per product for a provisional product licence. While modest, fees are recurring and should be budgeted in regulatory planning.
Regulation 14 provides enforcement. Any person who contravenes or fails to comply with Regulations 7, 8, 9, 10, or 11, or fails to comply with a direction under Regulation 12, commits an offence. On conviction, the person is liable to a fine not exceeding $2,000. For practitioners, the key point is that the penalty provision is linked to specific compliance duties—meaning breaches of reporting, recordkeeping, and withholding directions can trigger criminal liability.
How Is This Legislation Structured?
The Regulations are structured as a sequence of operational rules moving from licensing to post-licensing compliance and enforcement. They begin with definitions (Regulation 2), then set validity periods for product and import licences (Regulations 3 and 4). They proceed to application mechanics (Regulations 5 and 6), then impose ongoing notification duties for changes, new information, adverse effects, and withdrawal (Regulations 7–10). They then address compliance infrastructure through recordkeeping (Regulation 11), provide a regulatory intervention mechanism for suspected substandard products (Regulation 12), and conclude with administrative fees (Regulation 13) and criminal penalties (Regulation 14).
Who Does This Legislation Apply To?
The Regulations apply to persons involved in importing veterinary medicinal products and to holders of product licences or provisional product licences. Regulation 2 defines an “importer” as an importer of veterinary medicinal products. Regulation 11 specifically targets importers for recordkeeping and inspection readiness.
Meanwhile, Regulations 7–10 impose duties on the holder of a product licence or provisional product licence. In practice, this may include manufacturers, local distributors, or other entities that hold regulatory authorisations. The scope is therefore role-dependent: importers must maintain records and comply with withholding directions, while licence holders must manage change control, safety reporting, and withdrawal notifications.
Why Is This Legislation Important?
For practitioners, the Regulations matter because they translate regulatory policy into concrete compliance obligations with clear triggers. The licensing validity rules (five years for product licences; two years for provisional licences) affect renewal strategy and long-term market access. The consignment-based import licence rule (one consignment per licence, valid for one month) affects logistics, customs clearance planning, and risk management around shipment timing.
Equally important are the ongoing duties. Regulation 7’s “forthwith” notification requirement for material changes, Regulation 8’s duty to report information casting doubt on safety/quality/efficacy data, and Regulation 9’s adverse effects reporting obligation create a continuous compliance cycle. These provisions are often where regulatory breaches occur—particularly when product formulations, manufacturing processes, or evidence bases evolve over time.
Finally, the enforcement architecture is practical. Recordkeeping for five years and the ability to withhold suspected substandard products provide the licensing authority with tools for rapid intervention. Although the maximum fine is capped at $2,000, the real-world impact can be more significant: withholding directions can disrupt supply chains, trigger reputational harm, and create downstream liability under broader medicines regulation. Counsel should therefore treat these Regulations as part of a wider compliance program, not as isolated administrative rules.
Related Legislation
- Medicines Act (Chapter 176) — including Section 74 (authorising the making of these Regulations)
- Medicines (Veterinary Medicinal Products) — other subsidiary legislation (as applicable to licensing, product control, and enforcement under the Medicines Act)
Source Documents
This article provides an overview of the Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.